Abbott's study links Libre tech to reduced heart-related hospitalizations

Abbott's study links Libre tech to reduced heart-related hospitalizations

Abbott has announced findings from its REFLECT studies, which reveal that the use of FreeStyle Libre continuous glucose monitoring (CGM) technology is linked to a significant reduction in hospitalizations for heart complications among individuals with diabetes. The studies indicate that this CGM technology can reduce cardiovascular complication severity in people with Type 1 diabetes, irrespective of their history with low blood sugar events or …

Machine Learning-Based Prediction of Hypoglycemia Severity in Hospitalized Diabetic Patients

Objective: To identify risk factors for hypoglycemia in hospitalized patients with type 2 diabetes mellitus (T2DM) and develop predictive models for hypoglycemia severity based on machine learning algorithms. Methods: Adult non-pregnant hospitalized pat...

Abbott's studies show CGM technology linked to lower heart hospitalisation risk

Abbott's REFLECT studies indicate that FreeStyle Libre use is linked to a decrease in hospitalisation risk for heart complications.The post Abbott’s studies show CGM technology linked to lower heart hospitalisation risk appeared first on Clinical Trials Arena.

Freestyle Libre CGM Linked With Reduced Hospitalization Risk For Heart Complications in Patients With Diabetes

Abbott’s continuous glucose monitoring system is the first to show a reduction in cardiovascular complication severity.

Study links Abbott CGM use to fewer heart issue hospitalizations

The FreeStyle Libre is linked with fewer hospitalizations from heart complications in people with diabetes. [Image courtesy of Abbott]Abbott (NYSE:ABT) today announced results from real-world studies demonstrating benefits with its FreeStyle Libre continuous glucose monitoring (CGM) technology. Results from the REFLECT studies show that Libre CGM is associated with a significant reduction in the risk of hospitalization for heart complications in…